1. Scrip
  2. >>Business

Amgen’s Repatha Passes CVOT Test, But Contribution To 2017 Sales Growth Unclear

 
• By Mandy Jackson

Amgen’s PCSK9 inhibitor Repatha succeeded in the FOURIER cardiovascular outcomes study, but the data may not impact the company’s revenue until 2018 – after a potential revenue decline in 2017.

Amgen Inc. delivered a mixed bag of news to investors on Feb. 2, first revealing that the cholesterol-lowering therapy Repatha (evolocumab) passed its much-anticipated cardiovascular outcomes test, then reporting 2017 financial guidance that suggests the company will continue to see slow uptake for the PCSK9 inhibitor while sales for key products slump in the face of competition.

Repatha met the primary composite endpoint in the FOURIER cardiovascular outcomes trial (CVOT), showing a benefit versus placebo in statin-treated...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By Kevin Grogan

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

In Brief: Opus Gears Up For FDA Filing In Presbyopia

 
• By Sushmita Panda

Data from a second pivotal trial support a filing in the US for Opus Genetics’ phentolamine ophthalmic solution, to treat presbyopia.

BlissBio Goes Solo On HER2-Targeting ADC After Eisai Exit

 
• By Dexter Jie Yan

BlissBio is to single-handedly move BB-1701, its eribulin-containing, HER2-targeting antibody-drug conjugate, into a global pivotal Phase II/III program for HER2-expressing, Enhertu-resistant breast cancer.